VCU Massey study: Protein-based combination therapy overcomes tumor resistance to colorectal cancer treatment

Rectal cancer incidence rising after decades of decline as colorectal cancer shifts toward younger generations, ACS report finds

Colorectal cancer rates in the U.S. are moving in two very different directions, according to a report released from the American Cancer Society.

March 06, 2026

Vol.52 No.09

Drugs & Targets

FDA approves Braftovi combination regimen in first-line metastatic colorectal cancer

FDA granted full approval to Braftovi (encorafenib) in combination with cetuximab (Erbitux) and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation based on results from the global phase III BREAKWATER trial.

February 27, 2026

Vol.52 No.08

Black History Month Podcast

Malcolm V. Brock on his journey from Bermuda to Japan to the U.S. to England–and from Japanese studies to thoracic oncology
“When it gets down to brass tacks, relationships between each other, we’re all one.”

Malcolm V. Brock, director of Clinical and Translational Research in Thoracic Surgery at Johns Hopkins Kimmel Comprehensive Cancer Center, grew up in Bermuda. His father insisted that his children branch outside the small island—the country has a population of just over 60,000 people—and challenge themselves abroad.

February 20, 2026

Vol.52 No.07

By Malcolm V. Brock, Robert A. Winn and Preston Willett

Clinical Roundup

Rybrevant leads to anti-tumor activity and durable responses in CRC, phase I/II follow-up results show

Longer follow-up results from the investigational phase Ib/II OrigAMI-1 study evaluating amivantamab-vmjw, a bispecific antibody targeting epidermal growth factor receptor and MET, in combination with FOLFOX or FOLFIRI chemotherapy in patients with RAS/BRAF wild-type metastatic colorectal cancer were presented during a poster session at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.

January 16, 2026

Vol.52 No.02

Clinical Roundup

Fred Hutch researchers launch free online tool to assess CRC risk

Fred Hutch Cancer Center researchers developed a new tool that enables anyone to immediately assess their colorectal cancer risk online. Called MyGeneRisk, the free, web-based calculator allows users to input basic health information, including lifestyle habits and genetic data, to estimate their risk.

January 09, 2026

Vol.52 No.1

In Brief

Dimple Patel joins VCU Massey as associate director for innovation, leadership, and professional development

Dimple Patel recently joined the executive leadership team at VCU Massey Comprehensive Cancer Center, where she will serve as the associate director for innovation, leadership, and professional development. Patel brings 25 years of leadership experience spanning six public and private institutions of higher education.

December 19, 2025

Vol.51 No.46

VCU Massey study: Protein-based combination therapy overcomes tumor resistance to colorectal cancer treatment

YOU MAY BE INTERESTED IN

Rectal cancer incidence rising after decades of decline as colorectal cancer shifts toward younger generations, ACS report finds

FDA approves Braftovi combination regimen in first-line metastatic colorectal cancer

Malcolm V. Brock on his journey from Bermuda to Japan to the U.S. to England–and from Japanese studies to thoracic oncology
“When it gets down to brass tacks, relationships between each other, we’re all one.”

Rybrevant leads to anti-tumor activity and durable responses in CRC, phase I/II follow-up results show

Fred Hutch researchers launch free online tool to assess CRC risk

Dimple Patel joins VCU Massey as associate director for innovation, leadership, and professional development

Renew today!

Subscriber content

Never miss an issue!

Login

VCU Massey study: Protein-based combination therapy overcomes tumor resistance to colorectal cancer treatment

YOU MAY BE INTERESTED IN

Rectal cancer incidence rising after decades of decline as colorectal cancer shifts toward younger generations, ACS report finds

FDA approves Braftovi combination regimen in first-line metastatic colorectal cancer

Malcolm V. Brock on his journey from Bermuda to Japan to the U.S. to England–and from Japanese studies to thoracic oncology“When it gets down to brass tacks, relationships between each other, we’re all one.”

Rybrevant leads to anti-tumor activity and durable responses in CRC, phase I/II follow-up results show

Fred Hutch researchers launch free online tool to assess CRC risk

Dimple Patel joins VCU Massey as associate director for innovation, leadership, and professional development

Never miss an issue!

Login

Malcolm V. Brock on his journey from Bermuda to Japan to the U.S. to England–and from Japanese studies to thoracic oncology
“When it gets down to brass tacks, relationships between each other, we’re all one.”